Feliqs

Executive Summary

Feliqs Corporation is a clinical-stage ophthalmology biotech company based in Tokyo, Japan, focused on developing innovative therapies for neonatal and age-related eye diseases. The company's lead candidate, FLQ-101, is currently in Phase 1b clinical studies in the U.S., targeting retinopathy of prematurity (ROP), a leading cause of blindness in premature infants. Feliqs is also exploring FLQ-101 for geographic atrophy and wet AMD, expanding its potential beyond neonatal indications. Founded in 2020, the company operates with a lean team of 10-50 employees and is privately held. With a strong scientific foundation and a clear focus on unmet medical needs in ophthalmology, Feliqs aims to translate novel discoveries into treatments that can significantly impact patients' lives. Feliqs' early-stage pipeline and strategic focus on both neonatal and age-related indications position it as a compelling player in the ophthalmic biotech space. The Phase 1b study for FLQ-101 is a critical milestone, with initial safety and efficacy data expected to inform further clinical development. While the company has not disclosed total funding or valuation, its progress in a niche yet high-demand area suggests potential for strategic partnerships or licensing deals. Key risks include the inherent uncertainty of early-stage clinical trials and competition from established ophthalmic therapies. However, if successful, FLQ-101 could address significant gaps in ROP treatment and later-stage AMD, offering substantial value to patients and investors alike.

Upcoming Catalysts (preview)

• Q3 2026Phase 1b interim data readout for FLQ-101 in ROP60% success
• TBDPotential partnership or licensing agreement for FLQ-10140% success
• Q4 2026Initiation of Phase 2a study for FLQ-101 in geographic atrophy or wet AMD30% success